Honeynaps announced Sep. 25, 2023, that its SOMNUM artificial intelligence (AI) sleep disease analysis algorithm received FDA approval. The software leverages deep learning-based AI to perform real-time analysis of vast volumes of biosignals.
About SOMNUM
SOMNUM is software intended to aid in the diagnosis of sleep and respiratory-related sleep disorders. It analyses previously recorded physiological data obtained during sleep studies. The software automates recognition of sleep stage, respiratory, arousal and leg movement events.
The software uses AI to analyze multi-channel/time series biosignals, which allows for the delivery of fast, accurate diagnostic information for providers. While the process of reading polysomnography results can take several hours by skilled personnel, Honeynaps’ AI solution performs real-time analysis of biosignals.
Honeynaps notes that, for respiratory events, apneas and hypopneas must be manually scored by a physician.
About sleep disorders
Sleep disorders are conditions that disrupt normal sleep patterns, affecting the quality, amount and timing of sleep. With an estimated 70 million people worldwide experiencing sleep disorders, these conditions can contribute to physical and mental health problems.
Read more industry news from the AASM.
